Great Novel Therapeutics Biotech & Medicals (ROCO:7427) ROCE % : -8.55% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Great Novel Therapeutics Biotech & Medicals's annualized ROCE % for the quarter that ended in Dec. 2023 was -8.55%.

Great Novel Therapeutics Biotech & Medicals ROCE % Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals ROCE % Chart

Great Novel Therapeutics Biotech & Medicals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-44.08

-33.32

-22.21

-19.60

-12.42

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial					-17.67	-29.33	-20.00	-13.43	-8.55

Great Novel Therapeutics Biotech & Medicals ROCE % Calculation

Great Novel Therapeutics Biotech & Medicals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-61.449	/	( ( (372.847 - 12.047)	+	(644.849 - 15.932) )	/ 2 )
	=	-61.449	/	( (360.8	+	628.917)	/ 2 )
	=	-61.449	/	494.8585
	=	-12.42 %

Great Novel Therapeutics Biotech & Medicals's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-54.828	/	( ( (686.152 - 32.89)	+	(644.849 - 15.932) )	/ 2 )
	=	-54.828	/	( ( 653.262	+	628.917 )	/ 2 )
	=	-54.828	/	641.0895
	=	-8.55 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Great Novel Therapeutics Biotech & Medicals ROCE % Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503

Website

http://www.gntbm.com.tw

Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines